{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:14:03Z","timestamp":1790705643218,"version":"4.1.0"},"reference-count":139,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T00:00:00Z","timestamp":1566604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Northern Portugal Regional Operational Programme (NORTE 2020), under the Portugal 2020 Partnership Agreement, by the European Regional Development Fund (FEDER), through the Competitiveness Factors Operational Programme (COMPETE)","award":["NORTE-01-0145-FEDER-000013; POCI-01-0145-FEDER-028159 and POCI-01-0145-FEDER-030782"],"award-info":[{"award-number":["NORTE-01-0145-FEDER-000013; POCI-01-0145-FEDER-028159 and POCI-01-0145-FEDER-030782"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cells"],"abstract":"<jats:p>The cancer metabolic reprogramming allows the maintenance of tumor proliferation, expansion and survival by altering key bioenergetics, biosynthetic and redox functions to meet the higher demands of tumor cells. In addition, several metabolites are also needed to perform signaling functions that further promote tumor growth and progression. These metabolic alterations have been exploited in different cancers, including acute myeloid leukemia, as novel therapeutic strategies both in preclinical models and clinical trials. Here, we review the complexity of acute myeloid leukemia (AML) metabolism and discuss how therapies targeting different aspects of cellular metabolism have demonstrated efficacy and how they provide a therapeutic window that should be explored to target the metabolic requirements of AML cells.<\/jats:p>","DOI":"10.3390\/cells8090967","type":"journal-article","created":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T04:38:23Z","timestamp":1566794303000},"page":"967","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Targeting Metabolic Reprogramming in Acute Myeloid Leukemia"],"prefix":"10.3390","volume":"8","author":[{"given":"Isabel","family":"Castro","sequence":"first","affiliation":[{"name":"Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4710-057 Braga, Portugal"},{"name":"ICVS\/3B\u2019s-PT Government Associate Laboratory, 4806-909 Braga\/Guimar\u00e3es, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bel\u00e9m","family":"Sampaio-Marques","sequence":"additional","affiliation":[{"name":"Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4710-057 Braga, Portugal"},{"name":"ICVS\/3B\u2019s-PT Government Associate Laboratory, 4806-909 Braga\/Guimar\u00e3es, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4130-7167","authenticated-orcid":false,"given":"Paula","family":"Ludovico","sequence":"additional","affiliation":[{"name":"Life and Health Sciences Research Institute (ICVS), School of Medicine, University of Minho, 4710-057 Braga, Portugal"},{"name":"ICVS\/3B\u2019s-PT Government Associate Laboratory, 4806-909 Braga\/Guimar\u00e3es, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2019,8,24]]},"reference":[{"key":"ref_1","unstructured":"(2019, April 24). Acute Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. Available online: https:\/\/www.nccn.org\/professionals\/physician_gls\/default.aspx."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1002\/ajh.25214","article-title":"Acute myeloid leukemia: 2019 update on risk-stratification and management","volume":"93","author":"Estey","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.cger.2015.08.010","article-title":"Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly","volume":"32","author":"Klepin","year":"2016","journal-title":"Clin. Geriatr. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1056\/NEJMoa1516192","article-title":"Genomic Classification and Prognosis in Acute Myeloid Leukemia","volume":"374","author":"Papaemmanuil","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1200\/JCO.2014.55.1564","article-title":"Acute myeloid leukemia and myelodysplastic syndromes in older adults","volume":"32","author":"Klepin","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Bose, P., Vachhani, P., and Cortes, J.E. (2017). Treatment of Relapsed\/Refractory Acute Myeloid Leukemia. Curr. Treat. Options Oncol.","DOI":"10.1007\/s11864-017-0456-2"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.bbabio.2017.02.001","article-title":"Cancer metabolism in space and time: Beyond the Warburg effect","volume":"1858","author":"Danhier","year":"2017","journal-title":"Biochim. Biophys. Acta Bioenerg."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1038\/nrc3038","article-title":"Otto Warburg\u2019s contributions to current concepts of cancer metabolism","volume":"11","author":"Koppenol","year":"2011","journal-title":"Nat. Rev. Cancer"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1189\/jlb.0710417","article-title":"The level of glycolytic metabolism in acute myeloid leukemia blasts at diagnosis is prognostic for clinical outcome","volume":"89","author":"Herst","year":"2011","journal-title":"J. Leukoc. Biol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2017.81","article-title":"High mTORC1 activity drives glycolysis addiction and sensitivity to G6PD inhibition in acute myeloid leukemia cells","volume":"31","author":"Poulain","year":"2017","journal-title":"Leukemia"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"4807","DOI":"10.1111\/jcmm.13737","article-title":"Signalling mechanisms that regulate metabolic profile and autophagy of acute myeloid leukaemia cells","volume":"22","author":"Pereira","year":"2018","journal-title":"J. Cell Mol. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1182\/blood-2014-02-554204","article-title":"A distinct glucose metabolism signature of acute myeloid leukemia with prognostic value","volume":"124","author":"Chen","year":"2014","journal-title":"Blood"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.leukres.2007.04.014","article-title":"Glycolytic metabolism confers resistance to combined all-trans retinoic acid and arsenic trioxide-induced apoptosis in HL60rho0 cells","volume":"32","author":"Herst","year":"2008","journal-title":"Leuk. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.7314\/APJCP.2014.15.4.1823","article-title":"HIF-1alpha and GLUT1 gene expression is associated with chemoresistance of acute myeloid leukemia","volume":"15","author":"Song","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"334","DOI":"10.3892\/ol.2016.4600","article-title":"Resistance to chemotherapy is associated with altered glucose metabolism in acute myeloid leukemia","volume":"12","author":"Song","year":"2016","journal-title":"Oncol Lett"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.ccell.2018.08.016","article-title":"Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells","volume":"34","author":"Ye","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Chapuis, N., Poulain, L., Birsen, R., Tamburini, J., and Bouscary, D. (2019). Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid Leukemia. Front. Oncol.","DOI":"10.3389\/fonc.2019.00405"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.cell.2008.08.021","article-title":"Cancer cell metabolism: Warburg and beyond","volume":"134","author":"Hsu","year":"2008","journal-title":"Cell"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.tibs.2015.12.001","article-title":"The Warburg Effect: How Does it Benefit Cancer Cells?","volume":"41","author":"Liberti","year":"2016","journal-title":"Trends Biochem. Sci."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"DeBerardinis, R.J., and Chandel, N.S. (2016). Fundamentals of cancer metabolism. Sci Adv.","DOI":"10.1126\/sciadv.1600200"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Tan, H.W.S., Sim, A.Y.L., and Long, Y.C. (2017). Glutamine metabolism regulates autophagy-dependent mTORC1 reactivation during amino acid starvation. Nat. Commun.","DOI":"10.1038\/s41467-017-00369-y"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cell.2008.11.044","article-title":"Bidirectional transport of amino acids regulates mTOR and autophagy","volume":"136","author":"Nicklin","year":"2009","journal-title":"Cell"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/nrc.2016.71","article-title":"From Krebs to clinic: Glutamine metabolism to cancer therapy","volume":"16","author":"Altman","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.redox.2017.04.018","article-title":"Teaching the basics of cancer metabolism: Developing antitumor strategies by exploiting the differences between normal and cancer cell metabolism","volume":"12","author":"Kalyanaraman","year":"2017","journal-title":"Redox Biol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1182\/blood-2013-03-493163","article-title":"Inhibiting glutamine uptake represents an attractive new strategy for treating acute myeloid leukemia","volume":"122","author":"Willems","year":"2013","journal-title":"Blood"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.cmet.2017.12.006","article-title":"As Extracellular Glutamine Levels Decline, Asparagine Becomes an Essential Amino Acid","volume":"27","author":"Pavlova","year":"2018","journal-title":"Cell Metab."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.ccell.2018.10.005","article-title":"Inhibition of Amino Acid Metabolism Selectively Targets Human Leukemia Stem Cells","volume":"34","author":"Jones","year":"2018","journal-title":"Cancer Cell"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1182\/blood-2016-02-695312","article-title":"Evolution of acute myelogenous leukemia stem cell properties after treatment and progression","volume":"128","author":"Ho","year":"2016","journal-title":"Blood"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2013.05.017","article-title":"Cellular fatty acid metabolism and cancer","volume":"18","author":"Currie","year":"2013","journal-title":"Cell Metab"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/nrc.2016.89","article-title":"The multifaceted roles of fatty acid synthesis in cancer","volume":"16","author":"Rohrig","year":"2016","journal-title":"Nat. Rev. Cancer"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Stuani, L., Riols, F., Millard, P., Sabatier, M., Batut, A., Saland, E., Viars, F., Tonini, L., Zaghdoudi, S., and Linares, L.K. (2018). Stable Isotope Labeling Highlights Enhanced Fatty Acid and Lipid Metabolism in Human Acute Myeloid Leukemia. Int J. Mol. Sci., 19.","DOI":"10.3390\/ijms19113325"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1182\/blood-2016-08-734798","article-title":"Leukemic blasts program bone marrow adipocytes to generate a protumoral microenvironment","volume":"129","author":"Shafat","year":"2017","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.stem.2016.06.001","article-title":"Leukemic Stem Cells Evade Chemotherapy by Metabolic Adaptation to an Adipose Tissue Niche","volume":"19","author":"Ye","year":"2016","journal-title":"Cell Stem Cell"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nrc3483","article-title":"Cancer metabolism: Fatty acid oxidation in the limelight","volume":"13","author":"Carracedo","year":"2013","journal-title":"Nat. Rev. Cancer"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.ebiom.2016.11.025","article-title":"High Expression of CPT1A Predicts Adverse Outcomes: A Potential Therapeutic Target for Acute Myeloid Leukemia","volume":"14","author":"Shi","year":"2016","journal-title":"EBioMedicine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1007\/s10495-015-1137-x","article-title":"Carnitine transporter CT2 (SLC22A16) is over-expressed in acute myeloid leukemia (AML) and target knockdown reduces growth and viability of AML cells","volume":"20","author":"Wu","year":"2015","journal-title":"Apoptosis"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nature08617","article-title":"Cancer-associated IDH1 mutations produce 2-hydroxyglutarate","volume":"462","author":"Dang","year":"2009","journal-title":"Nature"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Mardis, E.R., and Wilson, R.K. (2009). Cancer genome sequencing: A review. Hum. Mol. Genet.","DOI":"10.1093\/hmg\/ddp396"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"3636","DOI":"10.1200\/JCO.2010.28.3762","article-title":"IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication","volume":"28","author":"Paschka","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1200\/JCO.2009.27.3730","article-title":"IDH1 and IDH2 gene mutations identify novel molecular subsets within de novo cytogenetically normal acute myeloid leukemia: A Cancer and Leukemia Group B study","volume":"28","author":"Marcucci","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1056\/NEJMoa1112304","article-title":"Prognostic relevance of integrated genetic profiling in acute myeloid leukemia","volume":"366","author":"Patel","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","author":"Figueroa","year":"2010","journal-title":"Cancer Cell"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2749","DOI":"10.1182\/blood-2009-11-253070","article-title":"Distinct clinical and biologic characteristics in adult acute myeloid leukemia bearing the isocitrate dehydrogenase 1 mutation","volume":"115","author":"Chou","year":"2010","journal-title":"Blood"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1007\/s12185-013-1407-8","article-title":"Role of DNMT3A, TET2, and IDH1\/2 mutations in pre-leukemic stem cells in acute myeloid leukemia","volume":"98","author":"Chan","year":"2013","journal-title":"Int. J. Hematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"822","DOI":"10.3324\/haematol.2017.183525","article-title":"Clinical relevance of IDH1\/2 mutant allele burden during follow-up in acute myeloid leukemia. A study by the French ALFA group","volume":"103","author":"Ferret","year":"2018","journal-title":"Haematologica"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"4511","DOI":"10.1158\/1078-0432.CCR-16-2628","article-title":"Correlation Between Isocitrate Dehydrogenase Gene Aberrations and Prognosis of Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis","volume":"23","author":"Xu","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"819","DOI":"10.3324\/haematol.2009.013797","article-title":"Role of the PI3K\/AKT and mTOR signaling pathways in acute myeloid leukemia","volume":"95","author":"Park","year":"2010","journal-title":"Haematologica"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.chembiol.2017.08.028","article-title":"Targeting Metabolism for Cancer Therapy","volume":"24","author":"Luengo","year":"2017","journal-title":"Cell Chem. Biol."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"187","DOI":"10.4155\/ppa.15.3","article-title":"Novel drug therapies in myeloid leukemia","volume":"4","author":"Horne","year":"2015","journal-title":"Pharm Pat. Anal."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/blood-2006-12-061283","article-title":"Constitutive phosphoinositide 3-kinase\/Akt activation represents a favorable prognostic factor in de novo acute myelogenous leukemia patients","volume":"110","author":"Tamburini","year":"2007","journal-title":"Blood"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1182\/blood-2002-11-3429","article-title":"Survival of acute myeloid leukemia cells requires PI3 kinase activation","volume":"102","author":"Xu","year":"2003","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/ncb2763","article-title":"Signal integration by mTORC1 coordinates nutrient input with biosynthetic output","volume":"15","author":"Dibble","year":"2013","journal-title":"Nat. Cell Biol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.cell.2012.03.017","article-title":"mTOR signaling in growth control and disease","volume":"149","author":"Laplante","year":"2012","journal-title":"Cell"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1038\/nature09572","article-title":"The Lkb1 metabolic sensor maintains haematopoietic stem cell survival","volume":"468","author":"Gurumurthy","year":"2010","journal-title":"Nature"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"31428","DOI":"10.18632\/oncotarget.2947","article-title":"Proteolytic systems and AMP-activated protein kinase are critical targets of acute myeloid leukemia therapeutic approaches","volume":"6","author":"Fernandes","year":"2015","journal-title":"Oncotarget"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1111\/cas.12189","article-title":"Mechanistic \/ mammalian target protein of rapamycin signaling in hematopoietic stem cells and leukemia","volume":"104","author":"Hirao","year":"2013","journal-title":"Cancer Sci."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.semcdb.2014.09.011","article-title":"Growing knowledge of the mTOR signaling network","volume":"36","author":"Huang","year":"2014","journal-title":"Semin. Cell Dev. Biol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Visnjic, D., Dembitz, V., and Lalic, H. (2018). The role of AMPK\/mTOR modulators in therapy of acute myeloid leukemia. Curr Med. Chem.","DOI":"10.2174\/0929867325666180117105522"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.stem.2015.08.019","article-title":"AMPK Protects Leukemia-Initiating Cells in Myeloid Leukemias from Metabolic Stress in the Bone Marrow","volume":"17","author":"Saito","year":"2015","journal-title":"Cell Stem Cell"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.1016\/j.celrep.2015.04.063","article-title":"Co-activation of AMPK and mTORC1 Induces Cytotoxicity in Acute Myeloid Leukemia","volume":"11","author":"Sujobert","year":"2015","journal-title":"Cell Rep."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Sujobert, P., and Tamburini, J. (2016). Co-activation of AMPK and mTORC1 as a new therapeutic option for acute myeloid leukemia. Mol. Cell Oncol.","DOI":"10.1080\/23723556.2015.1071303"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"4262","DOI":"10.1182\/blood-2010-02-269837","article-title":"The LKB1\/AMPK signaling pathway has tumor suppressor activity in acute myeloid leukemia through the repression of mTOR-dependent oncogenic mRNA translation","volume":"116","author":"Green","year":"2010","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1038\/leu.2011.339","article-title":"The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia","volume":"26","author":"Willems","year":"2012","journal-title":"Leukemia"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1182\/blood-2004-06-2494","article-title":"Antileukemic activity of rapamycin in acute myeloid leukemia","volume":"105","author":"Recher","year":"2005","journal-title":"Blood"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1084\/jem.20101145","article-title":"The autophagy protein Atg7 is essential for hematopoietic stem cell maintenance","volume":"208","author":"Mortensen","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1182\/blood-2016-07-692707","article-title":"Autophagy, a key mechanism of oncogenesis and resistance in leukemia","volume":"129","author":"Auberger","year":"2017","journal-title":"Blood"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1615\/CritRevEukarGeneExpr.v21.i1.50","article-title":"Autophagy in tumor suppression and cancer therapy","volume":"21","author":"Kung","year":"2011","journal-title":"Crit Rev. Eukaryot. Gene Expr."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Watson, A.S., Riffelmacher, T., Stranks, A., Williams, O., De Boer, J., Cain, K., MacFarlane, M., McGouran, J., Kessler, B., and Khandwala, S. (2015). Autophagy limits proliferation and glycolytic metabolism in acute myeloid leukemia. Cell Death Discov., 1.","DOI":"10.1038\/cddiscovery.2015.8"},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Jin, J., Britschgi, A., Schlafli, A.M., Humbert, M., Shan-Krauer, D., Batliner, J., Federzoni, E.A., Ernst, M., Torbett, B.E., and Yousefi, S. (2018). Low Autophagy (ATG) Gene Expression Is Associated with an Immature AML Blast Cell Phenotype and Can Be Restored during AML Differentiation Therapy. Oxid Med. Cell Longev.","DOI":"10.1155\/2018\/1482795"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1038\/s41375-018-0102-4","article-title":"RET-mediated autophagy suppression as targetable co-dependence in acute myeloid leukemia","volume":"32","author":"Rudat","year":"2018","journal-title":"Leukemia"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/leu.2016.295","article-title":"Complete mutational spectrum of the autophagy interactome: A novel class of tumor suppressor genes in myeloid neoplasms","volume":"31","author":"Visconte","year":"2017","journal-title":"Leukemia"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"12950","DOI":"10.1073\/pnas.0903091106","article-title":"Acquired copy number alterations in adult acute myeloid leukemia genomes","volume":"106","author":"Walter","year":"2009","journal-title":"Proc. Natl Acad Sci U S A"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Folkerts, H., Hilgendorf, S., Wierenga, A.T.J., Jaques, J., Mulder, A.B., Coffer, P.J., Schuringa, J.J., and Vellenga, E. (2017). Inhibition of autophagy as a treatment strategy for p53 wild-type acute myeloid leukemia. Cell Death Dis.","DOI":"10.1038\/cddis.2017.317"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Liu, T., Kishton, R.J., Macintyre, A.N., Gerriets, V.A., Xiang, H., Liu, X., Abel, E.D., Rizzieri, D., Locasale, J.W., and Rathmell, J.C. (2014). Glucose transporter 1-mediated glucose uptake is limiting for B-cell acute lymphoblastic leukemia anabolic metabolism and resistance to apoptosis. Cell Death Dis.","DOI":"10.1038\/cddis.2014.493"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1158\/1078-0432.CCR-14-1088","article-title":"Targeting the metabolic plasticity of multiple myeloma with FDA-approved ritonavir and metformin","volume":"21","author":"Bajpai","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1158\/1535-7163.MCT-15-0163","article-title":"Antileukemic Activity of 2-Deoxy-d-Glucose through Inhibition of N-Linked Glycosylation in Acute Myeloid Leukemia with FLT3-ITD or c-KIT Mutations","volume":"14","author":"Larrue","year":"2015","journal-title":"Mol. Cancer Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.canlet.2016.04.040","article-title":"Metabolic alterations and drug sensitivity of tyrosine kinase inhibitor resistant leukemia cells with a FLT3\/ITD mutation","volume":"377","author":"Huang","year":"2016","journal-title":"Cancer Lett."},{"key":"ref_79","first-page":"1245","article-title":"Novel Oxidative Phosphorylation Inhibitor IACS-010759 Induces AMPK-Dependent Apoptosis of AML Cells","volume":"130","author":"Yang","year":"2017","journal-title":"Blood"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood-2015-01-621870","article-title":"Targeting glutaminolysis has antileukemic activity in acute myeloid leukemia and synergizes with BCL-2 inhibition","volume":"126","author":"Jacque","year":"2015","journal-title":"Blood"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4064","DOI":"10.1182\/blood.V128.22.4064.4064","article-title":"Gls Inhibitor CB-839 Modulates Cellular Metabolism in AML and Potently Suppresses AML Cell Growth When Combined with 5-Azacitidine","volume":"128","author":"Cai","year":"2016","journal-title":"Blood"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","article-title":"Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed\/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study","volume":"9","author":"Daver","year":"2019","journal-title":"Cancer Discov"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4062\/biomolther.2017.178","article-title":"Targeting Glutamine Metabolism for Cancer Treatment","volume":"26","author":"Choi","year":"2018","journal-title":"Biomol. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"79722","DOI":"10.18632\/oncotarget.12944","article-title":"Inhibiting glutaminase in acute myeloid leukemia: Metabolic dependency of selected AML subtypes","volume":"7","author":"Matre","year":"2016","journal-title":"Oncotarget"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"42664","DOI":"10.18632\/oncotarget.16844","article-title":"Synthetic lethality of glutaminolysis inhibition, autophagy inactivation and asparagine depletion in colon cancer","volume":"8","author":"Li","year":"2017","journal-title":"Oncotarget"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.exphem.2017.09.007","article-title":"Glutaminase inhibition improves FLT3 inhibitor therapy for acute myeloid leukemia","volume":"58","author":"Gregory","year":"2018","journal-title":"Exp. Hematol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"377","DOI":"10.2147\/tcrm.2006.2.4.377","article-title":"Azacytidine (Vidaza(R)) in the treatment of myelodysplastic syndromes","volume":"2","author":"Raj","year":"2006","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.cmet.2018.04.012","article-title":"Asparagine and Glutamine: Co-conspirators Fueling Metastasis","volume":"27","author":"Luo","year":"2018","journal-title":"Cell Metab."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood-2014-09-600643","article-title":"Arginine dependence of acute myeloid leukemia blast proliferation: A novel therapeutic target","volume":"125","author":"Mussai","year":"2015","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1158\/0008-5472.CAN-15-0202","article-title":"Drug Redeployment to Kill Leukemia and Lymphoma Cells by Disrupting SCD1-Mediated Synthesis of Monounsaturated Fatty Acids","volume":"75","author":"Southam","year":"2015","journal-title":"Cancer Res."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1182\/blood-2014-12-617498","article-title":"Targeting the leukemia cell metabolism by the CPT1a inhibition: Functional preclinical effects in leukemias","volume":"126","author":"Ricciardi","year":"2015","journal-title":"Blood"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.ccell.2015.05.007","article-title":"Broad Anti-tumor Activity of a Small Molecule that Selectively Targets the Warburg Effect and Lipogenesis","volume":"28","author":"Flaveny","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1182\/blood-2015-08-665125","article-title":"Targeting leukemia\u2019s \"fatty tooth\"","volume":"126","author":"Samudio","year":"2015","journal-title":"Blood"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1158\/0008-5472.CAN-14-2676","article-title":"Targeting Mitochondria with Avocatin B Induces Selective Leukemia Cell Death","volume":"75","author":"Lee","year":"2015","journal-title":"Cancer Res."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/annonc\/mdw013","article-title":"IDH mutations in cancer and progress toward development of targeted therapeutics","volume":"27","author":"Dang","year":"2016","journal-title":"Ann. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2013.12.016","article-title":"Proto-oncogenic role of mutant IDH2 in leukemia initiation and maintenance","volume":"14","author":"Kats","year":"2014","journal-title":"Cell Stem Cell"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1158\/2159-8290.CD-16-1034","article-title":"AG-221, a First-in-Class Therapy Targeting Acute Myeloid Leukemia Harboring Oncogenic IDH2 Mutations","volume":"7","author":"Yen","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1001\/jamaoncol.2017.4695","article-title":"Differentiation Syndrome Associated With Enasidenib, a Selective Inhibitor of Mutant Isocitrate Dehydrogenase 2: Analysis of a Phase 1\/2 Study","volume":"4","author":"Fathi","year":"2018","journal-title":"JAMA Oncol."},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Norsworthy, K.J., Mulkey, F., Ward, A.F., Przepiorka, D., Deisseroth, A.B., Farrell, A.T., and Pazdur, R. (2018). Incidence of Differentiation Syndrome with Ivosidenib (IVO) and Enasidenib (ENA) for Treatment of Patients with Relapsed or Refractory (R\/R) Isocitrate Dehydrogenase (IDH)1- or IDH2-Mutated Acute Myeloid Leukemia (AML): A Systematic Analysis By the U.S. Food and Drug Administration (FDA). Blood, 132.","DOI":"10.1182\/blood-2018-99-117426"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML","volume":"378","author":"DiNardo","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1182\/blood-2015-06-648071","article-title":"Azacitidine in AML: A treatment option?","volume":"126","author":"Huls","year":"2015","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1182\/blood-2015-01-621664","article-title":"International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts","volume":"126","author":"Dombret","year":"2015","journal-title":"Blood"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1056\/NEJMoa1605949","article-title":"TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes","volume":"375","author":"Welch","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2015-07-604512","article-title":"Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia","volume":"127","author":"Wouters","year":"2016","journal-title":"Blood"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1016\/S1470-2045(15)00038-8","article-title":"Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: A multicentre, randomised, dose-escalation phase 1 study","volume":"16","author":"Issa","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1038\/leu.2015.244","article-title":"A phase II study of decitabine and gemtuzumab ozogamicin in newly diagnosed and relapsed acute myeloid leukemia and high-risk myelodysplastic syndrome","volume":"30","author":"Daver","year":"2016","journal-title":"Leukemia"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1080\/17474086.2018.1420474","article-title":"A concise review of BCL-2 inhibition in acute myeloid leukemia","volume":"11","author":"Yogarajah","year":"2018","journal-title":"Expert Rev. Hematol"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1182\/blood.V128.22.102.102","article-title":"Safety and Efficacy of Venetoclax Plus Low-Dose Cytarabine in Treatment-Naive Patients Aged \u226565 Years with Acute Myeloid Leukemia","volume":"128","author":"Wei","year":"2016","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1038\/s41591-018-0233-1","article-title":"Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia","volume":"24","author":"Pollyea","year":"2018","journal-title":"Nat. Med."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","author":"Chan","year":"2015","journal-title":"Nat. Med."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/leu.2016.222","article-title":"HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia","volume":"31","author":"Kontro","year":"2017","journal-title":"Leukemia"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2679","DOI":"10.1182\/blood-2011-11-393934","article-title":"Targeting of mTORC1\/2 by the mTOR kinase inhibitor PP242 induces apoptosis in AML cells under conditions mimicking the bone marrow microenvironment","volume":"120","author":"Zeng","year":"2012","journal-title":"Blood"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2756","DOI":"10.1158\/1078-0432.CCR-07-1372","article-title":"A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies","volume":"14","author":"Rizzieri","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1080\/14728222.2017.1333600","article-title":"Inhibition of mTOR kinase as a therapeutic target for acute myeloid leukemia","volume":"21","author":"Tabe","year":"2017","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/nrm3522","article-title":"Amino acid signalling upstream of mTOR","volume":"14","author":"Jewell","year":"2013","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1083\/jcb.200403069","article-title":"The TSC1-2 tumor suppressor controls insulin-PI3K signaling via regulation of IRS proteins","volume":"166","author":"Harrington","year":"2004","journal-title":"J. Cell Biol."},{"key":"ref_118","first-page":"5282","article-title":"Up-regulation of VEGF and its receptor in refractory leukemia cells","volume":"8","author":"Wang","year":"2015","journal-title":"Int J. Clin. Exp. Pathol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1158\/0008-5472.CAN-17-1166","article-title":"VEGFR2-Mediated Reprogramming of Mitochondrial Metabolism Regulates the Sensitivity of Acute Myeloid Leukemia to Chemotherapy","volume":"78","author":"Caiado","year":"2018","journal-title":"Cancer Res."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1517\/14728222.2012.694869","article-title":"Targeting the liver kinase B1\/AMP-activated protein kinase pathway as a therapeutic strategy for hematological malignancies","volume":"16","author":"Martelli","year":"2012","journal-title":"Expert Opin. Ther. Targets"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"e275","DOI":"10.1038\/cddis.2012.13","article-title":"Therapeutic metformin\/AMPK activation blocked lymphoma cell growth via inhibition of mTOR pathway and induction of autophagy","volume":"3","author":"Shi","year":"2012","journal-title":"Cell Death Dis."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1038\/leu.2013.107","article-title":"Mitochondrial energetic and AKT status mediate metabolic effects and apoptosis of metformin in human leukemic cells","volume":"27","author":"Scotland","year":"2013","journal-title":"Leukemia"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1002\/jcb.25559","article-title":"Targeting the mTOR Pathway in Leukemia","volume":"117","author":"Dinner","year":"2016","journal-title":"J. Cell Biochem."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.blre.2017.11.006","article-title":"Dueling for dual inhibition: Means to enhance effectiveness of PI3K\/Akt\/mTOR inhibitors in AML","volume":"32","author":"Herschbein","year":"2018","journal-title":"Blood Rev."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","article-title":"mTOR Signaling in Growth, Metabolism, and Disease","volume":"169","author":"Saxton","year":"2017","journal-title":"Cell"},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Rothe, K., Porter, V., and Jiang, X. (2019). Current Outlook on Autophagy in Human Leukemia: Foe in Cancer Stem Cells and Drug Resistance, Friend in New Therapeutic Interventions. Int J. Mol. Sci., 20.","DOI":"10.3390\/ijms20030461"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1182\/blood-2010-06-288589","article-title":"FIP200 is required for the cell-autonomous maintenance of fetal hematopoietic stem cells","volume":"116","author":"Liu","year":"2010","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1182\/blood-2016-01-692244","article-title":"Atg7 suppression enhances chemotherapeutic agent sensitivity and overcomes stroma-mediated chemoresistance in acute myeloid leukemia","volume":"128","author":"Piya","year":"2016","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Liu, Q., Chen, L., Atkinson, J.M., Claxton, D.F., and Wang, H.G. (2016). Atg5-dependent autophagy contributes to the development of acute myeloid leukemia in an MLL-AF9-driven mouse model. Cell Death Dis.","DOI":"10.1038\/cddis.2016.264"},{"key":"ref_130","doi-asserted-by":"crossref","unstructured":"Porter, A.H., Leveque-El Mouttie, L., Vu, T., Bruedigam, C., Sutton, J., Jacquelin, S., Hill, G.R., MacDonald, K.P.A., and Lane, S.W. (2017). Acute myeloid leukemia stem cell function is preserved in the absence of autophagy. Haematologica.","DOI":"10.3324\/haematol.2017.166389"},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1080\/15548627.2017.1287652","article-title":"Autophagy is dispensable for Kmt2a\/Mll-Mllt3\/Af9 AML maintenance and anti-leukemic effect of chloroquine","volume":"13","author":"Chen","year":"2017","journal-title":"Autophagy"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1182\/blood-2015-12-684696","article-title":"Cytoprotective autophagy maintains leukemia-initiating cells in murine myeloid leukemia","volume":"128","author":"Sumitomo","year":"2016","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/onc.2017.376","article-title":"Oncogenic FLT3-ITD supports autophagy via ATF4 in acute myeloid leukemia","volume":"37","author":"Heydt","year":"2018","journal-title":"Oncogene"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"5308","DOI":"10.1158\/1078-0432.CCR-07-5023","article-title":"The double-edged sword of autophagy modulation in cancer","volume":"15","author":"White","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_135","doi-asserted-by":"crossref","unstructured":"Bosnjak, M., Ristic, B., Arsikin, K., Mircic, A., Suzin-Zivkovic, V., Perovic, V., Bogdanovic, A., Paunovic, V., Markovic, I., and Bumbasirevic, V. (2014). Inhibition of mTOR-dependent autophagy sensitizes leukemic cells to cytarabine-induced apoptotic death. PLoS ONE.","DOI":"10.1371\/journal.pone.0094374"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/15548627.2016.1245263","article-title":"Targeting autophagy to overcome chemoresistance in acute myleogenous leukemia","volume":"13","author":"Piya","year":"2017","journal-title":"Autophagy"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/leu.2014.242","article-title":"Resistance prediction in AML: Analysis of 4601 patients from MRC\/NCRI, HOVON\/SAKK, SWOG and MD Anderson Cancer Center","volume":"29","author":"Walter","year":"2015","journal-title":"Leukemia"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1182\/blood-2017-09-801498","article-title":"Minimal\/measurable residual disease in AML: A consensus document from the European LeukemiaNet MRD Working Party","volume":"131","author":"Schuurhuis","year":"2018","journal-title":"Blood"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1111\/ejh.12690","article-title":"Targeting of cell metabolism in human acute myeloid leukemia--more than targeting of isocitrate dehydrogenase mutations and PI3K\/AKT\/mTOR signaling?","volume":"96","author":"Hauge","year":"2016","journal-title":"Eur. J. Haematol."}],"container-title":["Cells"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/9\/967\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:13:39Z","timestamp":1760188419000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2073-4409\/8\/9\/967"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,24]]},"references-count":139,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,9]]}},"alternative-id":["cells8090967"],"URL":"https:\/\/doi.org\/10.3390\/cells8090967","relation":{},"ISSN":["2073-4409"],"issn-type":[{"value":"2073-4409","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,24]]}}}